$CUE
Cue Biopharma, Inc.

2024 Q2 Form 10-Q Financial Statement

#000095017024056838 Filed on May 09, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1
Revenue $2.658M $1.717M
YoY Change 92.33% 818.18%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.511M $4.186M
YoY Change -17.37% 0.24%
% of Gross Profit
Research & Development $9.530M $10.20M
YoY Change -10.52% 8.6%
% of Gross Profit
Depreciation & Amortization $100.0K $96.00K
YoY Change -24.24% -44.83%
% of Gross Profit
Operating Expenses $13.04M $14.39M
YoY Change -12.47% 6.03%
Operating Profit -$10.38M -$12.67M
YoY Change -23.19% -5.32%
Interest Expense $427.0K $33.00K
YoY Change 22.0% -90.01%
% of Operating Profit
Other Income/Expense, Net $212.0K $321.0K
YoY Change -36.14% 18.45%
Pretax Income -$10.17M -$12.35M
YoY Change -22.86% -5.81%
Income Tax
% Of Pretax Income
Net Earnings -$10.17M -$12.35M
YoY Change -22.86% -5.81%
Net Earnings / Revenue -382.66% -719.1%
Basic Earnings Per Share -$0.20 -$0.25
Diluted Earnings Per Share -$0.20 -$0.25
COMMON SHARES
Basic Shares Outstanding 48.64M 48.64M
Diluted Shares Outstanding 50.17M 49.47M

Balance Sheet

Concept 2024 Q2 2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $60.03M $82.03M
YoY Change 3.7% 23.91%
Cash & Equivalents $30.03M $41.03M
Short-Term Investments $30.00M $41.00M
Other Short-Term Assets $2.024M $2.240M
YoY Change 5.91% -5.08%
Inventory
Prepaid Expenses
Receivables $1.847M $1.400M
Other Receivables $0.00 $0.00
Total Short-Term Assets $33.90M $44.67M
YoY Change -44.37% -35.03%
LONG-TERM ASSETS
Property, Plant & Equipment $667.0K $754.0K
YoY Change -44.04% -43.09%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $111.0K $114.0K
YoY Change -9.76% -8.8%
Total Long-Term Assets $8.429M $9.282M
YoY Change -31.07% -28.2%
TOTAL ASSETS
Total Short-Term Assets $33.90M $44.67M
Total Long-Term Assets $8.429M $9.282M
Total Assets $42.33M $53.95M
YoY Change -42.14% -33.95%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.906M $3.919M
YoY Change 65.79% 82.19%
Accrued Expenses $4.562M $5.208M
YoY Change 11.92% 83.19%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $37.00K
YoY Change
Long-Term Debt Due $4.000M $4.000M
YoY Change 0.0% 33.33%
Total Short-Term Liabilities $16.46M $18.09M
YoY Change 0.93% 30.99%
LONG-TERM LIABILITIES
Long-Term Debt $2.286M $3.244M
YoY Change -62.63% -54.16%
Other Long-Term Liabilities $1.962M $2.579M
YoY Change -58.56% -55.37%
Total Long-Term Liabilities $2.286M $3.244M
YoY Change -62.63% -54.16%
TOTAL LIABILITIES
Total Short-Term Liabilities $16.46M $18.09M
Total Long-Term Liabilities $2.286M $3.244M
Total Liabilities $20.71M $23.91M
YoY Change -23.76% -10.32%
SHAREHOLDERS EQUITY
Retained Earnings -$323.7M -$313.5M
YoY Change 16.97% 18.96%
Common Stock $345.3M $343.6M
YoY Change 6.99% 7.83%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $21.62M $30.04M
YoY Change
Total Liabilities & Shareholders Equity $42.33M $53.95M
YoY Change -42.14% -33.95%

Cashflow Statement

Concept 2024 Q2 2024 Q1
OPERATING ACTIVITIES
Net Income -$10.17M -$12.35M
YoY Change -22.86% -5.81%
Depreciation, Depletion And Amortization $100.0K $96.00K
YoY Change -24.24% -44.83%
Cash From Operating Activities -$9.990M -$9.784M
YoY Change -3.67% -9.68%
INVESTING ACTIVITIES
Capital Expenditures $10.00K $55.00K
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change -100.0% -100.0%
Cash From Investing Activities -$10.00K -$55.00K
YoY Change -100.2% -100.37%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -1.000M 2.354M
YoY Change -147.6% 506.7%
NET CHANGE
Cash From Operating Activities -9.990M -9.784M
Cash From Investing Activities -10.00K -55.00K
Cash From Financing Activities -1.000M 2.354M
Net Change In Cash -11.00M -7.485M
YoY Change 236.39% -264.25%
FREE CASH FLOW
Cash From Operating Activities -$9.990M -$9.784M
Capital Expenditures $10.00K $55.00K
Free Cash Flow -$10.00M -$9.839M
YoY Change -3.58% -9.18%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001645460
CY2024Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q1 dei Amendment Flag
AmendmentFlag
false
CY2024Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q1 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2023#LicenseMember
CY2023Q1 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2023#LicenseMember
CY2024Q1 dei Document Type
DocumentType
10-Q
CY2024Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q1 dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
CY2024Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q1 dei Entity File Number
EntityFileNumber
001-38327
CY2024Q1 dei Entity Registrant Name
EntityRegistrantName
Cue Biopharma, Inc.
CY2024Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2024Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-3324577
CY2024Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
40 Guest Street
CY2024Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Boston
CY2024Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2024Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02135
CY2024Q1 dei City Area Code
CityAreaCode
617
CY2024Q1 dei Local Phone Number
LocalPhoneNumber
949-2680
CY2024Q1 dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
CY2024Q1 dei Trading Symbol
TradingSymbol
CUE
CY2024Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2024Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2024Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2024Q1 dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
48643316
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
41029000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
48514000
CY2024Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1400000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1698000
CY2024Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2240000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1242000
CY2024Q1 us-gaap Assets Current
AssetsCurrent
44669000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
51454000
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
754000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
795000
CY2024Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5573000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
6323000
CY2024Q1 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
2690000
CY2023Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
2690000
CY2024Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
151000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
151000
CY2024Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
114000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
117000
CY2024Q1 us-gaap Assets
Assets
53951000
CY2023Q4 us-gaap Assets
Assets
61530000
CY2024Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
3919000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3501000
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5208000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4137000
CY2024Q1 cue Research And Development Contract Liability Current
ResearchAndDevelopmentContractLiabilityCurrent
1790000
CY2023Q4 cue Research And Development Contract Liability Current
ResearchAndDevelopmentContractLiabilityCurrent
2112000
CY2024Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3210000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3368000
CY2024Q1 us-gaap Other Long Term Debt Current
OtherLongTermDebtCurrent
3963000
CY2023Q4 us-gaap Other Long Term Debt Current
OtherLongTermDebtCurrent
3963000
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
18090000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
17081000
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2579000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3162000
CY2024Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
3244000
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
4202000
CY2024Q1 us-gaap Liabilities
Liabilities
23913000
CY2023Q4 us-gaap Liabilities
Liabilities
24445000
CY2024Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q1 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
48643316
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
48643316
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
47215116
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
47215116
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
48000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
47000
CY2024Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
343527000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
338228000
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-313537000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-301190000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
30038000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
37085000
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
53951000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
61530000
CY2024Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1717000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
187000
CY2024Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4186000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4176000
CY2024Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10199000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9391000
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
14385000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
13567000
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-12668000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-13380000
CY2024Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
562000
CY2023Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
641000
CY2024Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-241000
CY2023Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-370000
CY2024Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
321000
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
271000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-12347000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-13109000
CY2024Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
0
CY2023Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
57000
CY2024Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12347000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13052000
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.25
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.25
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.29
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.29
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
49466711
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
49466711
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44652353
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44652353
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
65683000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1998000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
388000
CY2023Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
57000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-13109000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
55017000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
37085000
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
3354000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1946000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-12347000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
30038000
CY2024Q1 us-gaap Profit Loss
ProfitLoss
-12347000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-13109000
CY2024Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
99000
CY2023Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
177000
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1946000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1998000
CY2024Q1 cue Change In Operating Lease Right Of Use Asset
ChangeInOperatingLeaseRightOfUseAsset
750000
CY2023Q1 cue Change In Operating Lease Right Of Use Asset
ChangeInOperatingLeaseRightOfUseAsset
703000
CY2024Q1 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
0
CY2023Q1 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
2000
CY2024Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
0
CY2023Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
-149000
CY2024Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
9000
CY2023Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
9000
CY2024Q1 cue Accretion Of Final Payment On Term Loan
AccretionOfFinalPaymentOnTermLoan
33000
CY2023Q1 cue Accretion Of Final Payment On Term Loan
AccretionOfFinalPaymentOnTermLoan
33000
CY2024Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-298000
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
139000
CY2024Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
998000
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1518000
CY2024Q1 cue Increase Decrease In Deposit Liabilities
IncreaseDecreaseInDepositLiabilities
0
CY2023Q1 cue Increase Decrease In Deposit Liabilities
IncreaseDecreaseInDepositLiabilities
139000
CY2024Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
418000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-580000
CY2024Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1071000
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-709000
CY2024Q1 cue Increase Decrease In Research And Development Contract Liability
IncreaseDecreaseInResearchAndDevelopmentContractLiability
-322000
CY2023Q1 cue Increase Decrease In Research And Development Contract Liability
IncreaseDecreaseInResearchAndDevelopmentContractLiability
2966000
CY2024Q1 cue Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-741000
CY2023Q1 cue Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-652000
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9784000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10833000
CY2024Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
55000
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0
CY2024Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0
CY2023Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
2000
CY2024Q1 cue Payments For Redemption Of Short Term Investments
PaymentsForRedemptionOfShortTermInvestments
0
CY2023Q1 cue Payments For Redemption Of Short Term Investments
PaymentsForRedemptionOfShortTermInvestments
-15000000
CY2024Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-55000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
15002000
CY2024Q1 cue Proceeds From At Time Market Offering Net Of Commission And Fees
ProceedsFromAtTimeMarketOfferingNetOfCommissionAndFees
3354000
CY2023Q1 cue Proceeds From At Time Market Offering Net Of Commission And Fees
ProceedsFromAtTimeMarketOfferingNetOfCommissionAndFees
0
CY2024Q1 cue Payment Of Term Loan
PaymentOfTermLoan
-1000000
CY2023Q1 cue Payment Of Term Loan
PaymentOfTermLoan
0
CY2024Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
CY2023Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
388000
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2354000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
388000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-7485000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
4557000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
48665000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
51764000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
41180000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
56321000
CY2024Q1 us-gaap Interest Paid Net
InterestPaidNet
209000
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
330000
CY2024Q1 us-gaap Marketable Securities
MarketableSecurities
41000000
CY2024Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates include estimates related to collaboration revenue, the accounting for potential liabilities and accrued expenses, the assumptions utilized in valuing stock-based compensation issued for services, the realization of deferred tax assets, and the useful life with respect to long-lived assets and intangibles. Actual results could differ from those estimates.</span></p>
CY2024Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
0
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
0
CY2024Q1 us-gaap Acquired Finite Lived Intangible Assets Weighted Average Useful Life
AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
P15Y
CY2024Q1 cue Pre Funded Warrants
PreFundedWarrants
1531440
CY2024Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
18459072
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
16233005
CY2024Q1 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
41000000
CY2023Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
39100000
CY2024Q1 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
41000000
CY2023Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
39100000
CY2024Q1 cue Fair Value Assets Among Level2 And Level3 Transfers Amount
FairValueAssetsAmongLevel2AndLevel3TransfersAmount
0
CY2023Q4 cue Fair Value Assets Among Level2 And Level3 Transfers Amount
FairValueAssetsAmongLevel2AndLevel3TransfersAmount
0
CY2024Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4465000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4411000
CY2024Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3711000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3616000
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
754000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
795000
CY2024Q1 us-gaap Depreciation
Depreciation
96000
CY2023Q1 us-gaap Depreciation
Depreciation
174000
CY2024Q1 cue Amortization Of Trademark
AmortizationOfTrademark
3000
CY2023Q1 cue Amortization Of Trademark
AmortizationOfTrademark
3000
CY2024Q1 cue Cash Obligation
CashObligation
20000000
CY2024Q1 us-gaap Interest Expense Other
InterestExpenseOther
199000
CY2023Q1 us-gaap Interest Expense Other
InterestExpenseOther
330000
CY2024Q1 us-gaap Interest Expense
InterestExpense
33000
CY2023Q1 us-gaap Interest Expense
InterestExpense
33000
CY2024Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
3000000
CY2024Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
4000000
CY2024Q1 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
7000000
CY2024Q1 us-gaap Long Term Debt
LongTermDebt
3000000
CY2024Q1 cue Accretion Of Final Payment
AccretionOfFinalPayment
272000
CY2024Q1 us-gaap Deferred Finance Costs Current Gross
DeferredFinanceCostsCurrentGross
28000
CY2024Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
3244000
CY2024Q1 us-gaap Long Term Debt Current
LongTermDebtCurrent
4000000
CY2024Q1 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
-37000
CY2024Q1 us-gaap Other Long Term Debt Current
OtherLongTermDebtCurrent
3963000
CY2024Q1 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
142000
CY2024Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
9000
CY2023Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
9000
CY2024Q1 us-gaap Short Term Borrowings
ShortTermBorrowings
37000
CY2024Q1 us-gaap Other Short Term Borrowings
OtherShortTermBorrowings
28000
CY2024Q1 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
3106000
CY2023Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
2219000
CY2024Q1 cue Accrued Contract Research Services Current
AccruedContractResearchServicesCurrent
1816000
CY2023Q4 cue Accrued Contract Research Services Current
AccruedContractResearchServicesCurrent
1411000
CY2024Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
207000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
344000
CY2024Q1 cue Accrued Contract Manufacturing Services Current
AccruedContractManufacturingServicesCurrent
79000
CY2023Q4 cue Accrued Contract Manufacturing Services Current
AccruedContractManufacturingServicesCurrent
163000
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5208000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4137000
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0383
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0428
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.6627
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.0986
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.034
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0399
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.97
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.004
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7492917
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.41
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y1M13D
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1869500
CY2024Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.02
CY2024Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2024Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
91751
CY2024Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
10.63
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
9270666
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.1
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y8M26D
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
5085904
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
9.85
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P4Y8M19D
CY2024Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
10600000
CY2023Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
12800000
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
3.2
CY2024Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1946000
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1998000
CY2019Q2 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
2500000
CY2019Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
400000
CY2020Q4 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
1250000
CY2021Q4 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
3000000
CY2024Q1 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
100000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
2529000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2799000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
818000
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
6146000
CY2024Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
357000
CY2024Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
5789000
CY2024Q1 cue Operating Leases Rent Expenses Net
OperatingLeasesRentExpensesNet
900000
CY2023Q1 cue Operating Leases Rent Expenses Net
OperatingLeasesRentExpensesNet
900000
CY2024Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y11M4D
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y1M28D
CY2024Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0618
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0625
CY2024Q1 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0000950170-24-056838-index-headers.html Edgar Link pending
0000950170-24-056838-index.html Edgar Link pending
0000950170-24-056838.txt Edgar Link pending
0000950170-24-056838-xbrl.zip Edgar Link pending
cue-20240331.htm Edgar Link pending
cue-20240331.xsd Edgar Link pending
cue-ex31_1.htm Edgar Link pending
cue-ex31_2.htm Edgar Link pending
cue-ex32_1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img77944571_0.jpg Edgar Link pending
img77944571_1.jpg Edgar Link pending
img77944571_2.jpg Edgar Link pending
img77944571_3.jpg Edgar Link pending
img77944571_4.jpg Edgar Link pending
img77944571_5.jpg Edgar Link pending
img77944571_6.jpg Edgar Link pending
img77944571_7.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
cue-20240331_htm.xml Edgar Link completed
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending